
|Articles|September 27, 2014
- Head and Neck Cancers (Issue 2)
- Volume 2
- Issue 1
Immune Checkpoint Inhibitors for Head and Neck Cancers
Author(s)Barbara Burtness, MD
Barbara Burtness, MD, discusses immune checkpoint inhibitors for head and neck cancers.
Advertisement
Articles in this issue
about 11 years ago
Treatment Update: Unresectable Medullary Thyroid Cancerabout 11 years ago
Sequencing Sorafenib and Lenvatinib in Thyroid Cancerabout 11 years ago
The Side Effects of Lenvatinibabout 11 years ago
Battling the Immunosuppressive Nature of Head and Neck CancerAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































